To discuss the current treatment landscape for migraines and the use of the following oral therapeutics:
Pfizer’s Nurtec (rimegepant)
AbbVie’s Ubrelvy (ubrogepant)
AbbVie’s Qulipta (atogepant)
Pfizer’s Zavzpret (zavegepant)
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the current treatment landscape and use of oral medications for migraines.
Ticker(s): PFE, ABBVWho's the expert?
Institution: Private Practice
- Manages 35-40 patients monthly with migraines
- Is oderately familiar. Has prescribed it once, will prescribe again
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
